Current Research

Articles from the National Institutes of Health

Cannabidiol in Anxiety and Sleep: A Large Case Series
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6326553/

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223703/

Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143706/

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.
https://www.ncbi.nlm.nih.gov/pubmed/28861514

Overcoming the Bell-Shaped Dose-Response of Cannabidiol by Using Cannabis Extract
https://www.scirp.org/journal/PaperInformation.aspx?paperID=53912

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425583/

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165946/

Alcohol Extracts vs CO2 Extracts
http://www.evolvedalchemy.com/co2-vs-alcohol-extractions/

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?
https://www.ncbi.nlm.nih.gov/pubmed/22625422

​Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.
https://www.ncbi.nlm.nih.gov/pubmed/27256343

​Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804326

Antibacterial cannabinoids from Cannabis sativa: a structure‐activity study.
http://www.ncbi.nlm.nih.gov/pubmed/18681481

CBD compound in cannabis could treat diabetes, researchers suggest
https://www.diabetes.co.uk/news/2015/apr/cbd-compound-in-cannabis-could-treat-diabetes,-researchers-suggest-95335970.html

Regulation of nausea and vomiting by cannabinoids.
http://www.ncbi.nlm.nih.gov/pubmed/21175589

Interaction between non‐psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti‐ nausea or anti‐emetic effects of cannabidiol (CBD) in rats and shrews.
https://www.ncbi.nlm.nih.gov/pubmed/21243485

Cannabidiol, a non‐psychotropic component of cannabis, attenuates vomiting and nausea‐like behaviour via indirect agonism of 5‐HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus.
http://www.ncbi.nlm.nih.gov/pubmed/21827451

Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.
http://www.ncbi.nlm.nih.gov/pubmed/21238581

Pure cannabidiol in the treatment of malignant migrating partial seizures in infancy: a case
report. http://www.ncbi.nlm.nih.gov/pubmed/25882081

Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine.
http://www.ncbi.nlm.nih.gov/pubmed/25999668

Anti‐inflammatory effects of the cannabidiol derivative dimethylheptyl‐cannabidiol ‐ studies in BV‐2 microglia and encephalitogenic T cells.
http://www.ncbi.nlm.nih.gov/pubmed/26540221

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation
http://www.ncbi.nlm.nih.gov/pubmed/25703248

Anti‐inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS‐stimulated macrophages.
http://www.ncbi.nlm.nih.gov/pubmed/27215129

The nonpsychoactive Cannabis constituent cannabidiol is a wake‐inducing agent.
http://www.ncbi.nlm.nih.gov/pubmed/19045957

Potential Effects of Cannabidiol as a Wake‐Promoting Agent
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023456

Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury.
http://www.ncbi.nlm.nih.gov/pubmed/17890433

Cannabidiol as potential anticancer drug
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3579246

The Antitumor Activity of Plant‐Derived Non‐ Psychoactive Cannabinoids.
http://www.ncbi.nlm.nih.gov/pubmed/25916739

Cannabis and Cannabinoids
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0032740

Cannabinoids inhibit human keratinocyte proliferation through a non‐CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis.
http://www.ncbi.nlm.nih.gov/pubmed/17157480

The relationship between cannabidiol and psychosis: A review.
http://www.ncbi.nlm.nih.gov/pubmed/25954940

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
http://www.ncbi.nlm.nih.gov/pubmed/22716160

Could cannabidiol be used as an alternative to antipsychotics?
https://www.ncbi.nlm.nih.gov/pubmed/27267317

Cannabidiol attenuates haloperidol‐induced catalepsy and c‐Fos protein expression in the dorsolateral striatum via 5‐HT1A receptors in mice.
http://www.ncbi.nlm.nih.gov/pubmed/27131780

Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158779

A systematic review of the antipsychotic properties of cannabidiol in humans.
https://www.ncbi.nlm.nih.gov/pubmed/25667194

Multiple mechanisms involved in the large‐spectrum therapeutic potential of cannabidiol in psychiatric disorders http://www.ncbi.nlm.nih.gov/pubmed/23108553

Cannabidiol Modulates Fear Memory Formation Through Interactions with Serotonergic Transmission in the Mesolimbic System.
https://www.ncbi.nlm.nih.gov/pubmed/27296152

Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
http://www.ncbi.nlm.nih.gov/pubmed/22729452

Endocannabinoid system: Role in depression, reward and pain control (Review).
http://www.ncbi.nlm.nih.gov/pubmed/27484193

Beyond the CB1 Receptor: Is Cannabidiol the Answer forDisorders of Motivation?
http://www.ncbi.nlm.nih.gov/pubmed/27023732

Does cannabidiol have a role in the treatment of schizophrenia? Cannabinoids and schizophrenia: therapeutic prospects.
http://www.ncbi.nlm.nih.gov/pubmed/23829368

The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer’s disease.
https://www.ncbi.nlm.nih.gov/pubmed/27471947

Long‐term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice.
https://www.ncbi.nlm.nih.gov/pubmed/25024347

Evidences for the anti‐panic actions of Cannabidiol.
http://www.ncbi.nlm.nih.gov/pubmed/27157263

Purified Cannabidiol, the main non‐psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis.
http://www.ncbi.nlm.nih.gov/pubmed/26744883

The Profile of Immune Modulation by Cannabidiol (CBD) Involves Deregulation of Nuclear Factor of Activated T Cells (NFAT)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2748879

Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.
http://www.ncbi.nlm.nih.gov/pubmed/27256343

CBD & Inflammatory Bowel Disease
http://cornerstonecollective.com/cbd‐inflammatory‐bowel‐disease

Cannabidiol, a Major Non‐Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts.
http://www.ncbi.nlm.nih.gov/pubmed/25801536

CBD‐enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience.
http://www.ncbi.nlm.nih.gov/pubmed/26800377

Perceived efficacy of cannabidiol‐enriched cannabis extracts for treatment of pediatric epilepsy: A potential role for infantile spasms and Lennox‐Gastaut syndrome.
http://www.ncbi.nlm.nih.gov/pubmed/25935511

Cannabidiol: Promise and Pitfalls
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189631

HU‐446 and HU‐465, Derivatives of the Non‐psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells.
http://www.ncbi.nlm.nih.gov/pubmed/26259697

A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis.
http://www.ncbi.nlm.nih.gov/pubmed/26489494

Transdermal cannabidiol reduces inflammation and pain‐ related behaviours in a rat model of arthritis.
http://www.ncbi.nlm.nih.gov/pubmed/26517407

Cannabidiol limits Tcell‐mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation.
http://www.ncbi.nlm.nih.gov/pubmed/26772776

Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.
http://www.ncbi.nlm.nih.gov/pubmed/27069631

Differential effectiveness of selected non‐psychotropic phytocannabinoids on human sebocyte functions implicates their introduction in dry/seborrheic skin and acne treatment.
http://www.ncbi.nlm.nih.gov/pubmed/27094344

Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria.
http://www.ncbi.nlm.nih.gov/pubmed/25595981

Cannabidiol improves lung function and inflammation in mice submitted to LPS‐induced acute lung injury.
http://www.ncbi.nlm.nih.gov/pubmed/25356537

Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double‐blind trial.
https://www.ncbi.nlm.nih.gov/pubmed/25237116